GUCD1

Summary

GUCD1 (guanylyl cyclase domain containing 1, HGNC:14237) is a protein-coding gene on chromosome 22q11.23, encoding Protein GUCD1 (Q96NT3).

Predicted to be involved in liver regeneration and response to cAMP.

Source: NCBI Gene 83606 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_001284254

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14237
Approved symbol	GUCD1
Name	guanylyl cyclase domain containing 1
Location	22q11.23
Locus type	gene with protein product
Status	Approved
Aliases	MGC1842, LLN4
Ensembl gene	ENSG00000138867
Ensembl biotype	protein_coding
OMIM	619171
Entrez	83606

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 9 protein_coding, 3 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000398245, ENST00000402766, ENST00000404664, ENST00000407471, ENST00000407973, ENST00000435822, ENST00000447813, ENST00000468170, ENST00000480272, ENST00000490810, ENST00000490922, ENST00000493099, ENST00000621833, ENST00000894495, ENST00000951439

RefSeq mRNA: 8 — MANE Select: NM_001284254 NM_001284251, NM_001284252, NM_001284253, NM_001284254, NM_001284255, NM_001284256, NM_001284257, NM_031444

CCDS: CCDS33621, CCDS63426, CCDS63427, CCDS74831, CCDS74832, CCDS74833

Canonical transcript exons

ENST00000435822 — 6 exons

Exon	Start	End
ENSE00000935754	24547908	24548073
ENSE00000935755	24546914	24547005
ENSE00001667374	24554949	24555138
ENSE00001789037	24540438	24543097
ENSE00003545500	24548917	24549001
ENSE00003684891	24543842	24544083

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 98.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.7014 / max 374.5581, expressed in 1810 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
193383	19.5298	1802
193385	5.8487	1725
193386	1.4065	1026
193384	1.3770	981
193382	0.5394	285

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	98.82	gold quality
oocyte	CL:0000023	98.51	gold quality
ileal mucosa	UBERON:0000331	98.36	gold quality
right lobe of liver	UBERON:0001114	98.02	gold quality
secondary oocyte	CL:0000655	97.83	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.75	gold quality
pancreatic ductal cell	CL:0002079	97.42	gold quality
mucosa of transverse colon	UBERON:0004991	97.40	gold quality
kidney epithelium	UBERON:0004819	97.37	gold quality
heart left ventricle	UBERON:0002084	97.33	gold quality
gastrocnemius	UBERON:0001388	97.20	gold quality
cardiac ventricle	UBERON:0002082	97.20	gold quality
left ventricle myocardium	UBERON:0006566	97.16	gold quality
liver	UBERON:0002107	97.15	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.87	gold quality
adult mammalian kidney	UBERON:0000082	96.67	gold quality
muscle of leg	UBERON:0001383	96.67	gold quality
small intestine	UBERON:0002108	96.54	gold quality
blood	UBERON:0000178	96.50	gold quality
stromal cell of endometrium	CL:0002255	96.39	gold quality
tibialis anterior	UBERON:0001385	96.35	gold quality
body of stomach	UBERON:0001161	96.25	gold quality
lower esophagus mucosa	UBERON:0035834	96.17	gold quality
transverse colon	UBERON:0001157	96.12	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.10	gold quality
metanephros cortex	UBERON:0010533	96.09	gold quality
lower esophagus	UBERON:0013473	96.09	gold quality
duodenum	UBERON:0002114	95.98	gold quality
quadriceps femoris	UBERON:0001377	95.97	gold quality
jejunal mucosa	UBERON:0000399	95.89	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	18.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

85 targeting GUCD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-940	99.37	66.14	2064

Literature-anchored findings (GeneRIF, showing 2)

• The expression and function of a ubiquitous protein, GUCD1, were characterized, it might have a role in regulating normal and abnormal cell growth in the liver. (PMID:24743017)
• miR-370 suppressed Hepatocellular carcinoma cell metastasis and epithelial-mesenchymal transition via regulating GUCD1. (PMID:30799589)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gucd1	ENSDARG00000068438
mus_musculus	Gucd1	ENSMUSG00000033416
rattus_norvegicus	Gucd1	ENSRNOG00000049952
drosophila_melanogaster	CG13760	FBGN0040375

Protein

Protein identifiers

Protein GUCD1 — Q96NT3 (reviewed: Q96NT3)

Alternative names: Guanylyl cyclase domain-containing protein 1, Protein LLN4

All UniProt accessions (6): A0A087WVD9, B4DL90, B5MCF3, E7EX77, E9PGZ7, Q96NT3

UniProt curated annotations — full annotation on UniProt →

Isoforms (3)

UniProt ID	Names	Canonical?
Q96NT3-1	1	yes
Q96NT3-2	2
Q96NT3-3	3

RefSeq proteins (8): NP_001271180, NP_001271181, NP_001271182, NP_001271183, NP_001271184, NP_001271185, NP_001271186, NP_113632 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018616	GUCD1	Family

Pfam: PF09778

UniProt features (4 total): splice variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96NT3-F1	86.92	0.67

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 177 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, IVANOVA_HEMATOPOIESIS_MATURE_CELL, MORI_IMMATURE_B_LYMPHOCYTE_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, BURTON_ADIPOGENESIS_5, SENESE_HDAC3_TARGETS_DN, NUYTTEN_EZH2_TARGETS_DN, LU_EZH2_TARGETS_UP, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, BAKKER_FOXO3_TARGETS_UP, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK, RAO_BOUND_BY_SALL4_ISOFORM_A, PECE_MAMMARY_STEM_CELL_UP, GSE13522_WT_VS_IFNAR_KO_SKING_T_CRUZI_Y_STRAIN_INF_DN

GO Biological Process (2): response to cAMP (GO:0051591), liver regeneration (GO:0097421)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to purine-containing compound	1
response to organophosphorus	1
response to oxygen-containing compound	1
liver development	1
animal organ regeneration	1
binding	1

Protein interactions and networks

STRING

344 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GUCD1	ZNF652	Q9Y2D9	603
GUCD1	LRRC75B	Q2VPJ9	591
GUCD1	C22orf15	Q8WYQ4	577
GUCD1	DCTN4	Q9UJW0	499
GUCD1	DRICH1	Q6PGQ1	474
GUCD1	ADD3	Q9UEY8	432
GUCD1	ZNF70	Q9UC06	393
GUCD1	PALMD	Q9NP74	390
GUCD1	GSTT4	A0A1W2PR19	376
GUCD1	DDTL	A6NHG4	371
GUCD1	CLU	P10909	371
GUCD1	SMIM24	O75264	364
GUCD1	TM4SF4	P48230	351
GUCD1	RGL4	Q8IZJ4	349
GUCD1	CLUL1	Q15846	348

IntAct

33 interactions, top by confidence:

A	B	Type	Score
GUCD1	NGLY1	psi-mi:“MI:0915”(physical association)	0.670
NGLY1	GUCD1	psi-mi:“MI:0915”(physical association)	0.670
CRX	GUCD1	psi-mi:“MI:0915”(physical association)	0.560
TCF4	GUCD1	psi-mi:“MI:0915”(physical association)	0.560
GUCD1	CTH	psi-mi:“MI:0915”(physical association)	0.560
GUCD1	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.560
GUCD1	KRT40	psi-mi:“MI:0915”(physical association)	0.560
GUCD1	CRX	psi-mi:“MI:0915”(physical association)	0.560
CTH	GUCD1	psi-mi:“MI:0915”(physical association)	0.560
GUCD1	TCF4	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-7	GUCD1	psi-mi:“MI:0915”(physical association)	0.560
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
PCNA	GUCD1	psi-mi:“MI:0915”(physical association)	0.370
IMPDH1	LCMT2	psi-mi:“MI:0914”(association)	0.350
GORASP1	CLASP2	psi-mi:“MI:0914”(association)	0.350
AMIGO1	TMEM223	psi-mi:“MI:0914”(association)	0.350
GORASP1	RTCA	psi-mi:“MI:0914”(association)	0.350
GUCD1	HNRNPA1L2	psi-mi:“MI:0914”(association)	0.350
GORASP1	PRORP	psi-mi:“MI:0914”(association)	0.350
SLC15A1	MEN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (145): GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), KRT40 (Two-hybrid), KRTAP10-7 (Two-hybrid), GUCD1 (Affinity Capture-MS), GUCD1 (Affinity Capture-MS), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid), GUCD1 (Two-hybrid)

ESM2 similar proteins: A1A5C7, A5D7H1, A6H7A0, A8MUP2, B0BMW8, B0CM95, B0KWE9, B1MTH4, B2KI79, F1LTR1, O43688, O94925, P17553, P52875, P55244, P56703, P57791, Q16763, Q1RML1, Q28D01, Q2HJ61, Q3UHH2, Q3ZCD7, Q4L208, Q4R8V4, Q4V899, Q5R6I6, Q5R890, Q5SP67, Q66H54, Q86YN1, Q8BZH0, Q8BZI6, Q8K593, Q8R4D1, Q8VDI9, Q91ZH7, Q96H72, Q96NT3, Q9DAX2

Diamond homologs: Q8BZI6, Q8L870, Q96NT3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NEDD4	“down-regulates quantity by destabilization”	GUCD1	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1038 predictions. Top by Δscore:

Variant	Effect	Δscore
22:24543101:C:CC	acceptor_gain	1.0000
22:24543107:G:GC	acceptor_gain	1.0000
22:24543834:GCACT:G	donor_loss	1.0000
22:24543836:ACTCA:A	donor_loss	1.0000
22:24543837:CTCA:C	donor_loss	1.0000
22:24543838:TCA:T	donor_loss	1.0000
22:24543839:CA:C	donor_loss	1.0000
22:24543840:A:AC	donor_gain	1.0000
22:24543840:ACGG:A	donor_loss	1.0000
22:24543840:ACGGT:A	donor_gain	1.0000
22:24543841:C:CG	donor_gain	1.0000
22:24543841:CG:C	donor_gain	1.0000
22:24543841:CGG:C	donor_gain	1.0000
22:24543841:CGGT:C	donor_gain	1.0000
22:24543841:CGGTC:C	donor_gain	1.0000
22:24544079:CTGTG:C	acceptor_gain	1.0000
22:24544084:C:CC	acceptor_gain	1.0000
22:24546908:GCTC:G	donor_loss	1.0000
22:24546909:CTCA:C	donor_loss	1.0000
22:24546910:TCACC:T	donor_loss	1.0000
22:24546911:CAC:C	donor_loss	1.0000
22:24546912:A:AC	donor_gain	1.0000
22:24546912:A:T	donor_loss	1.0000
22:24546913:C:CA	donor_loss	1.0000
22:24546913:C:CC	donor_gain	1.0000
22:24547001:AAGGA:A	acceptor_gain	1.0000
22:24547002:AGGA:A	acceptor_gain	1.0000
22:24547004:GA:G	acceptor_gain	1.0000
22:24547006:C:CC	acceptor_gain	1.0000
22:24547904:TCA:T	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000063217 (22:24542467 T>C), RS1000070163 (22:24555808 G>C), RS1000258656 (22:24542112 C>T), RS1000351879 (22:24554766 C>G,T), RS1000384492 (22:24555086 T>C), RS1000441110 (22:24547443 C>A,T), RS1000506272 (22:24553152 T>G), RS1000654850 (22:24553521 C>G), RS1000680578 (22:24546446 G>C), RS1001016809 (22:24546186 C>T), RS1001066748 (22:24543614 G>A), RS1001249058 (22:24549519 T>C), RS1001385860 (22:24556002 C>A,G,T), RS1002073795 (22:24544831 G>A), RS1002271642 (22:24544468 G>A)

Disease associations

OMIM: gene MIM:619171 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): cerebellar ataxia (MONDO:0000437)

Orphanet (1): Rare ataxia (Orphanet:102002)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002481_6	Acne (severe)	6.000000e-07
GCST90013407_62	Liver enzyme levels (gamma-glutamyl transferase)	5.000000e-32

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004532	serum gamma-glutamyl transferase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002524	Cerebellar Ataxia	C10.228.140.252.190; C10.597.350.090.500; C23.888.592.350.090.200

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol S	decreases methylation, affects cotreatment, increases expression	2
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases oxidation, increases abundance	1
bisphenol A	affects cotreatment, increases expression	1
titanium dioxide	increases expression	1
beta-lapachone	decreases expression, increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
methacrylaldehyde	affects cotreatment, increases expression, increases oxidation, increases abundance	1
pentanal	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
abrine	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Acrolein	increases oxidation, increases abundance, affects cotreatment, increases expression	1
Air Pollutants	affects cotreatment, increases abundance, increases expression, increases oxidation	1
Vehicle Emissions	decreases expression, increases abundance	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ozone	increases expression, increases oxidation, increases abundance, affects cotreatment	1
Quercetin	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	affects expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cyclosporine	decreases expression	1
Gold Compounds	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

146 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00950196	PHASE4	COMPLETED	Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
NCT04107740	PHASE4	COMPLETED	C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
NCT01970098	PHASE3	COMPLETED	A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970111	PHASE3	COMPLETED	An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970124	PHASE3	COMPLETED	A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970137	PHASE3	COMPLETED	A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT02889302	PHASE3	COMPLETED	An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT03408080	PHASE3	ACTIVE_NOT_RECRUITING	Open Pilot Trial of BHV-4157
NCT03701399	PHASE3	ACTIVE_NOT_RECRUITING	Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03901638	PHASE3	TERMINATED	Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
NCT07040137	PHASE3	RECRUITING	Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
NCT00034242	PHASE2	COMPLETED	High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
NCT00202397	PHASE2	COMPLETED	Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
NCT00863538	PHASE2	COMPLETED	Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01004016	PHASE2	COMPLETED	A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01350440	PHASE2	COMPLETED	Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
NCT02540655	PHASE2	COMPLETED	Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia
NCT03932669	PHASE2	COMPLETED	Effect of Nilotinib in Cerebellar Ataxia Patients
NCT04301284	PHASE2	WITHDRAWN	Study of CAD-1883 for Spinocerebellar Ataxia
NCT05125666	PHASE2	UNKNOWN	Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection
NCT06397274	PHASE2	NOT_YET_RECRUITING	Stemchymal® for Polyglutamine Spinocerebellar Ataxia
NCT00683943	PHASE1	COMPLETED	Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
NCT02287064	PHASE1	UNKNOWN	An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
NCT05157802	PHASE1	ACTIVE_NOT_RECRUITING	Promoting Physical Activity Engagement for People With Early-stage Cerebellar Ataxia
NCT01104649	PHASE2/PHASE3	COMPLETED	Efficacy of Riluzole in Hereditary Cerebellar Ataxia
NCT02960893	PHASE2/PHASE3	COMPLETED	Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
NCT00244361	PHASE1/PHASE2	COMPLETED	Effectiveness of Rituximab in Pediatric OMS Patients.
NCT01649687	PHASE1/PHASE2	COMPLETED	Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells
NCT01958177	PHASE1/PHASE2	UNKNOWN	Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia
NCT02829268	PHASE1/PHASE2	COMPLETED	A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
NCT00001324	Not specified	COMPLETED	PET Scan to Study Brain Control of Human Movement
NCT00006492	Not specified	COMPLETED	Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia
NCT00136630	Not specified	COMPLETED	Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
NCT00140829	Not specified	COMPLETED	SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias
NCT00272272	Not specified	COMPLETED	Fall Prevention in a Geriatric Nursing Home Setting Using the Music of Nolwenn Leroy
NCT00654251	Not specified	COMPLETED	Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
NCT00692861	Not specified	COMPLETED	Autoimmunity in Neurologic Complications of Celiac Disease
NCT01037777	Not specified	COMPLETED	RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
NCT01307176	Not specified	COMPLETED	Exercise Training Program for Cerebellar Ataxia
NCT01428531	Not specified	COMPLETED	Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment